Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5744 - Irinotecan, oxaliplatin, 5-fluorouracil/leucovorin (FOLFIRINOX) as first-line therapy in advanced HER2-negative gastric or gastroesophageal adenocarcinoma (G/GEA)

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Cytotoxic Therapy

Tumour Site

Gastric Cancer

Presenters

Ekaterina Obarevich

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

E. Obarevich, N. Besova, E. Trusilova, V. Gorbunova

Author affiliations

  • Chemotherapy Department, N. N. Blokhin Russian Cancer Research Center, 115478 - Moscow/RU

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5744

Background

G/GEA is relatively chemosensitive, but triplet chemotherapy (CT) regimens with docetaxel have the most efficacy with overall response rate (ORR) 37-58%, median progression free survival (MPFS) 5.2-9.7 mo, median overall survival 9.2-18.8 mo. Irinotecan is active drug for the 1st line CT of G/GEA patients (pts). FOLFIRINOX regimen have shown promising activity in other GI cancers (pancreatic, colorectal). The aim of our study was to evaluate efficacy and tolerability of mFOLFIRINOX in G/GEA.

Methods

G/GEA patients (pts) received 9 cycles of irinotecan 180mg/m2+oxaliplatin 85mg/m2+leucovorin 200mg/m2+5-fluorouracil 250mg/m2 bolus followed by 2200mg/m2x48h (mFOLFIRINOX) on d1 every 2 weeks without subsequent maintenance therapy. Primary G-CSF prophylaxis was not provided.

Results

108 CT-naïve pts with G/GEA were included from Jan 2012 to Oct 2015 (48 female, 60 male). ECOG 0/1/2/3/4 were 41/51/7/1% pts. ORR was 52,8%, SD–39,8%, PD–5,6%. MPFS and MOS were 7,83 mo and 16,8 mo, respectively. The main toxicities Grade(gr) ≥3 in pts included neutropenia–47,2%, febrile neutropenia–5,6%, diarrhea–5,6%; we noted else thrombocytopenia gr 1-2 - 29,6%, asthenia gr 1-3 - 87%, hepatotoxicity - 25%/gr 3–0,9%, neurotoxicity–15,7%/gr–1,9%. 31(28,7%) pts received G-CSF on 8,5% cycles. There were no deaths and treatment discontinuation due to toxicity. After the complete regression of distant metastases 11 pts were operated (D2 gastrectomy). For these pts MPFS was18,47 mo, MOS–29,33 mo.

Conclusions

mFOLFIRINOX showed remarkable ORR, PFS and OS in patients with advanced gastroesophageal or gastric adenocarcinoma in the fist-line setting. This regimen may be one more reasonable therapeutic option for these pts. We recommend mFOLFIRINOX for Phase III clinical trial compared with FLOT regimen.

Clinical trial identification

Legal entity responsible for the study

Besova N.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.